Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 3.13B 2.75B 2.54B 2.35B 4.45B 300B 4.53B 30.51B 11.85B 147B 11.77B 11.51B 510B | P/E 2026 * |
-9.2x | P/E 2027 * | -9.14x |
|---|---|---|---|---|---|
| Enterprise Value | 2.55B 2.24B 2.06B 1.91B 3.62B 244B 3.69B 24.82B 9.65B 119B 9.58B 9.37B 415B | EV / Sales 2026 * |
968x | EV / Sales 2027 * | 220x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 29/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 31/08/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 31/03/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 30/11/2008 |
Harry Penner
CHM | Chairman | 80 | 04/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 29/02/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 3.13B | |
| -0.24% | +1.85% | +3.13% | +8.40% | 49.74B | |
| -0.36% | +1.21% | +420.77% | +597.43% | 40.49B | |
| -2.29% | +3.83% | +23.48% | +56.80% | 34.35B | |
| -2.13% | +0.29% | +23.91% | -7.13% | 34.75B | |
| -0.79% | +2.02% | +3.83% | +36.42% | 26.98B | |
| +3.82% | +3.51% | - | - | 16.58B | |
| -2.62% | -2.13% | +64.96% | +120.02% | 15.6B | |
| -2.17% | +6.65% | +104.31% | +102.15% | 14.27B | |
| -2.70% | -2.04% | +12.37% | +17.77% | 13.76B | |
| Average | +0.01% | +3.99% | +82.09% | +116.48% | 27.39B | |
| Weighted average by Cap. | -1.10% | +4.37% | +93.96% | +134.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.63M 2.31M 2.13M 1.97M 3.74M 252M 3.81M 25.65M 9.97M 123M 9.89M 9.68M 429M | 11.96M 10.49M 9.69M 8.95M 16.97M 1.15B 17.31M 116M 45.25M 561M 44.92M 43.94M 1.95B |
| Net income | -330M -289M -267M -247M -468M -31.6B -477M -3.21B -1.25B -15.47B -1.24B -1.21B -53.69B | -370M -325M -300M -277M -525M -35.48B -536M -3.61B -1.4B -17.36B -1.39B -1.36B -60.26B |
| Net Debt | -584M -512M -473M -437M -828M -55.93B -845M -5.69B -2.21B -27.37B -2.19B -2.15B -95.01B | -507M -445M -411M -380M -720M -48.58B -734M -4.94B -1.92B -23.77B -1.91B -1.86B -82.53B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
